PT  - JOURNAL ARTICLE
AU  - Aram Ter-Sarkisov
TI  - One Shot Model For The Prediction of COVID-19 and Lesions Segmentation In Chest CT Scans Through The Affinity Among Lesion Mask Features
AID  - 10.1101/2020.12.29.20248987
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.12.29.20248987
4099  - http://medrxiv.org/content/early/2021/01/04/2020.12.29.20248987.short
4100  - http://medrxiv.org/content/early/2021/01/04/2020.12.29.20248987.full
AB  - We introduce a model that segments lesions and predicts COVID-19 from chest CT scans through the derivation of an affinity matrix between lesion masks. The novelty of the methodology is based on the computation of the affinity between the lesion masks’ features extracted from the image. First, a batch of vectorized lesion masks is constructed. Then, the model learns the parameters of the affinity matrix that captures the relationship between features in each vector. Finally, the affinity is expressed as a single vector of pre-defined length. Without any complicated data manipulation, class balancing tricks, and using only a fraction of the training data, we achieve a 91.74% COVID-19 sensitivity, 85.35% common pneumonia sensitivity, 97.26% true negative rate and 91.94% F1-score. Ablation studies show that the method can quickly generalize to new datasets. All source code, models and results are publicly available on https://github.com/AlexTS1980/COVID-Affinity-Model.Competing Interest StatementThe authors have declared no competing interest.Funding StatementN/AAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOpen source, referenced in text